JP2023515576A5 - - Google Patents
Info
- Publication number
- JP2023515576A5 JP2023515576A5 JP2022551290A JP2022551290A JP2023515576A5 JP 2023515576 A5 JP2023515576 A5 JP 2023515576A5 JP 2022551290 A JP2022551290 A JP 2022551290A JP 2022551290 A JP2022551290 A JP 2022551290A JP 2023515576 A5 JP2023515576 A5 JP 2023515576A5
- Authority
- JP
- Japan
- Prior art keywords
- epilepsy
- alkyl
- group
- hydrogen
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982830P | 2020-02-28 | 2020-02-28 | |
| US202062982838P | 2020-02-28 | 2020-02-28 | |
| US202062982804P | 2020-02-28 | 2020-02-28 | |
| US62/982,804 | 2020-02-28 | ||
| US62/982,838 | 2020-02-28 | ||
| US62/982,830 | 2020-02-28 | ||
| PCT/US2021/019814 WO2021173930A1 (en) | 2020-02-28 | 2021-02-26 | Kcnt1 inhibitors and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023515576A JP2023515576A (ja) | 2023-04-13 |
| JP2023515576A5 true JP2023515576A5 (enExample) | 2024-03-04 |
| JP7699836B2 JP7699836B2 (ja) | 2025-06-30 |
Family
ID=77492026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551290A Active JP7699836B2 (ja) | 2020-02-28 | 2021-02-26 | Ｋｃｎｔ１阻害剤、および使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12583849B2 (enExample) |
| EP (2) | EP4692069A3 (enExample) |
| JP (1) | JP7699836B2 (enExample) |
| KR (1) | KR20230005813A (enExample) |
| CN (1) | CN115443129A (enExample) |
| BR (1) | BR112022017191A2 (enExample) |
| CA (1) | CA3169779A1 (enExample) |
| IL (1) | IL295940A (enExample) |
| MX (1) | MX2022010625A (enExample) |
| WO (1) | WO2021173930A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3139063A1 (en) * | 2019-05-03 | 2020-11-12 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| WO2020227097A1 (en) * | 2019-05-03 | 2020-11-12 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| US11773088B2 (en) | 2020-11-02 | 2023-10-03 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| US20240368142A1 (en) * | 2021-04-29 | 2024-11-07 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| US20260109692A1 (en) | 2024-10-18 | 2026-04-23 | UCB Biopharma SRL | Kcnt1 inhibitors and methods of use |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| DE19929076A1 (de) | 1999-06-25 | 2000-12-28 | Aventis Pharma Gmbh | Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| GB0127547D0 (en) | 2001-11-16 | 2002-01-09 | Astrazeneca Ab | Chemical compounds |
| TW200301698A (en) | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
| US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| JP2005060255A (ja) | 2003-08-20 | 2005-03-10 | Nippon Nohyaku Co Ltd | カルボキサミド類及びこれを有効成分とする有害生物防除剤 |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| AU2005233642A1 (en) * | 2004-04-13 | 2005-10-27 | Astellas Pharma Inc. | Polycyclic pyridines as potassium ion channel modulators |
| AU2007275221A1 (en) | 2006-07-20 | 2008-01-24 | Allen J. Borchardt | Benzothiophene inhibitors of RHO kinase |
| US20080269241A1 (en) | 2007-02-15 | 2008-10-30 | Darin Allen | Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| CN101903349B (zh) | 2007-08-27 | 2014-01-08 | Abbvie德国有限责任两合公司 | 4-(4-吡啶基)-苯甲酰胺及其作为rock活性调节剂的应用 |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| JP6387360B2 (ja) | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン |
| US10167257B2 (en) | 2014-04-04 | 2019-01-01 | Iomet Pharma Ltd. | Indole derivatives for use in medicine |
| TW201642855A (zh) | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| US10538516B2 (en) * | 2015-03-25 | 2020-01-21 | National Center For Geriatrics And Gerontology | Oxadiazole derivative and pharmaceutical containing same |
| EP3438091A4 (en) | 2016-03-30 | 2019-11-27 | Ajinomoto Co., Inc. | CONNECTION WITH INCREASING ACTIVITY FOR ACTION OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR |
| WO2018187480A1 (en) * | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2020227097A1 (en) | 2019-05-03 | 2020-11-12 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| CA3139063A1 (en) * | 2019-05-03 | 2020-11-12 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| BR112021021921A2 (pt) | 2019-05-03 | 2021-12-28 | Nat Univ Singapore | Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica |
| AU2021241530A1 (en) | 2020-03-23 | 2022-10-20 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| KR20230035608A (ko) | 2020-07-06 | 2023-03-14 | 프락시스 프리시젼 메디신즈, 인크. | Kcnt1 억제제 및 사용 방법 |
| US11773088B2 (en) | 2020-11-02 | 2023-10-03 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| EP4267133A4 (en) | 2020-12-22 | 2025-01-22 | Praxis Precision Medicines, Inc. | KCNT1 INHIBITORS AND METHODS OF USE |
| US20240368142A1 (en) | 2021-04-29 | 2024-11-07 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| WO2023239839A1 (en) | 2022-06-08 | 2023-12-14 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use |
-
2021
- 2021-02-26 CA CA3169779A patent/CA3169779A1/en active Pending
- 2021-02-26 WO PCT/US2021/019814 patent/WO2021173930A1/en not_active Ceased
- 2021-02-26 EP EP25207650.0A patent/EP4692069A3/en active Pending
- 2021-02-26 CN CN202180028764.XA patent/CN115443129A/zh active Pending
- 2021-02-26 MX MX2022010625A patent/MX2022010625A/es unknown
- 2021-02-26 JP JP2022551290A patent/JP7699836B2/ja active Active
- 2021-02-26 BR BR112022017191A patent/BR112022017191A2/pt unknown
- 2021-02-26 US US17/904,963 patent/US12583849B2/en active Active
- 2021-02-26 KR KR1020227033876A patent/KR20230005813A/ko active Pending
- 2021-02-26 IL IL295940A patent/IL295940A/en unknown
- 2021-02-26 EP EP21760026.1A patent/EP4110317B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023515576A5 (enExample) | ||
| JP2022530989A5 (enExample) | ||
| JP2023518838A5 (enExample) | ||
| JP2023532985A5 (enExample) | ||
| KR102943760B1 (ko) | 피리다진 유도체 억제제, 및 그의 제조 방법 및 용도 | |
| JP2014524472A5 (enExample) | ||
| JP2022531388A5 (enExample) | ||
| EP3013815B1 (en) | Carbazole carboxamide compounds useful as kinase inhibitors | |
| JP2006513268A5 (ja) | アンタゴニスト活性を有するベンゾアゾリルピペラジン誘導体 | |
| JP2005514398A5 (enExample) | ||
| JP2021105002A5 (enExample) | ||
| JP2008524328A5 (enExample) | ||
| AR065276A1 (es) | Herbicidas de n-oxidos de piridina sustituidos | |
| JP2010505794A5 (enExample) | ||
| JP2006508107A5 (enExample) | ||
| JPWO2020017587A5 (enExample) | ||
| JP2011515482A5 (enExample) | ||
| JP2011503193A5 (enExample) | ||
| RU2015101532A (ru) | Замещенные бициклические алкокси-пиразольные аналоги в качестве аллостерических модуляторов рецепторов mglur5 | |
| JP2011079828A5 (enExample) | ||
| JP2008513413A5 (enExample) | ||
| HUP0102677A2 (hu) | Triszubsztituált imidazolszármazékok, eljárás az előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
| BR122023004130B1 (pt) | Compostos heteroaromáticos, composição farmacêutica e uso dos referidos compostos no tratamento de distúrbios mediados ou associados a dopamina d1 | |
| EA030410B1 (ru) | Замещенные конденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений | |
| JP2021518340A5 (enExample) |